Jefferson University Hospitals

Hepatitis C Center

Related Content
hepatitisccenter
  • Among the Nation's Best for Gastroenterology & GI Surgery
    Among the Nation's Best for Gastroenterology & GI Surgery
    U.S.News & World Report rated us among the nation's best for Gastroenterology & GI Surgery.
    Learn More >

Approximately 3.2 million Americans are infected with hepatitis C. The virus, which is primarily transmitted through contact with infected blood, attacks the liver and can cause cirrhosis and/or liver cancer when left untreated. There is currently no vaccine for hepatitis C.

Unfortunately, many people have no symptoms from infection and don't know they are infected until they develop signs of advanced liver disease. Because hepatitis C becomes chronic in more than 80 percent of cases, it is important to seek treatment from specialists who understand the condition and can work with you and your loved ones to establish the most appropriate treatment plan.

At the Jefferson Hepatitis C Center in Philadelphia, our expert hepatologists, pathologists, radiologists and other specialists will provide a coordinated approach to the management of your hepatitis C or coinfection of hepatitis C with hepatitis B and/or HIV.

Why Choose Jefferson for Hepatitis C Treatment in Philadelphia?

Our Hepatitis C Center features:

  • A tailored program to meet patient needs
  • Expert consultations for referring physicians and patients including a detailed plan highlighting potential drug interactions and treatment considerations
  • An active clinical trials program
  • A twice-weekly outpatient hepatitis C treatment clinic

New Treatments Available for Hepatitis C

Standard of care therapy for most patients with hepatitis C until 2011 included combination therapy with weekly pegylated interferon injections and ribavirin pills for 48 weeks. For many patients, this treatment was only successful less than 50 percent of the time.

Now, several new medications, called direct-acting antiviral agents, have been approved by the FDA for the treatment of hepatitis C. These interferon-free medications, which include protease, polymerase and NS5A inhibitors, act to directly block enzymes crucial to the replication (or growth) of the virus. By taking at least one of these new medications by mouth, the likelihood of treatment success increases dramatically, and treatment may even be shortened to as few as eight to 12 weeks for many patients, a real advancement in the treatment of this disease.

Many more medications are expected to hit the market in the next few years. There has never been a better time to be treated for hepatitis C.


Center Leadership